Viral vectored transmission blocking vaccines against Plasmodium falciparum by Kapulu, Melissa C et al.
ORAL PRESENTATION Open Access
Viral vectored transmission blocking vaccines
against Plasmodium falciparum
Melissa C Kapulu
1*, Sumi Biswas
1, Andrew Blagborough
2, Sarah C Gilbert
1, Robert E Sinden
2, Adrian VS Hill
1
From Parasite to Prevention: Advances in the understanding of malaria
Edinburgh, UK. 20-22 October 2010
Background
Transmission blocking vaccines (TBVs) target sexual
developÂ¬ment of the parasite within the mosquito and
aim to prevent transmission of malaria from one indivi-
dual to another. Antibodies raised against Pfs48/45,
Pfs230 Region C, PfHAP2, and Anopheles gambiae
Alanyl Aminopeptidase N1 (AgAPN1) proteins reduce
transmission i.e. have transmission blocking activity
[1-5]. Recombinant simian Adenovirus (AdC63 serotype)
and Modified Vaccinia Ankara (MVA) viral vectors have
been shown to induce high antibody titres to asexual
parasite antigens in animal studies [6].
Materials and methods
Protein sequences for each of the antigens were codon
optimised for expression in humans and cloned into
shuttle vectors, which were then recombined with the
parental virus and purified to obtain virus expressing
the antigen of interest. Mice were vaccinated with
AdC63 (i.m.), sera was taken after 2 weeks, and will be
followed by an MVA boost (i.d.) eight weeks after the
prime. Antibodies were assayed by a standardised
ELISA, and transmission blocking activity assessed using
a standardised membrane feeding assay (SMFA).
Conclusion
Induction of high antibody tires using this vaccine plat-
form could be used together with other control mea-
sures to achieve elimination and/or eradication of the
disease at a local or national level.
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